Top Qs
Timeline
Chat
Perspective
Crisugabalin
Drug for chronic pain From Wikipedia, the free encyclopedia
Remove ads
Crisugabalin (HSK16149) is a selective GABA analog in development for the treatment of chronic pain. It has a wider therapeutic index than pregabalin, which has a similar mechanism of action. In China, it was approved in May 2024 for the treatment of diabetic peripheral neuropathic pain[1] and approved in July 2024 for the treatment of postherpetic neuralgia.[2] In the United States, it is in Phase III trials as of 2023.[3][4] The drug can be administered with or without food.[5]
Remove ads
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads